The expanded field rights significantly increase the optionality and peak-revenue potential of Spyre's lead asset SPY003. Watch for any early pipeline expansion into new indications (e.g., psoriasis, psoriatic arthritis, ankylosing spondylitis) and for any material transaction that would accelerate the timeline for dosing outside IBD.
Price Chart
Executive Summary
Spyre Therapeutics expanded its license agreement with Paragon Therapeutics, removing the previous restriction that limited SPY003 (an IL-23p19 antibody) to inflammatory bowel disease. The new 'Field' covers all therapeutic areas, subject to dosing restrictions: no combination-trial dosing outside IBD before June 2028 and no monotherapy dosing outside IBD before June 2030. This materially increases the total addressable market for Spyre's lead asset, though the near-term clinical focus remains IBD.
Key Facts
- License field expanded from inflammatory bowel disease to all therapeutic areas (prophylaxis, palliation, treatment, diagnosis of all human diseases).
- Monotherapy dosing outside IBD restricted until June 1, 2030; combination dosing outside IBD restricted until June 1, 2028.
- If Spyre or the retained IL-23 project licensee consummates a material transaction (change of control or sale of lead IL-23p19 asset post-Phase II), the monotherapy restriction outside IBD terminates early on June 1, 2028.
- Amendment effective May 29, 2026; filed June 1, 2026.
Financial Impact
No financial terms disclosed. The amendment expands the addressable market for SPY003 from IBD-only to all therapeutic areas, substantially increasing peak revenue potential.
Risk Factors
- Dosing restrictions outside IBD remain in place until 2028 (combination) and 2030 (monotherapy), limiting near-term clinical expansion.
- No financial terms disclosed — the amendment could carry undisclosed milestone or royalty adjustments.
- Clinical development in new indications carries inherent trial risk and regulatory uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000075 |
| Document: syre-20260529.htm | 0001636282-26-000075 |
| Document: 0001636282-26-000075-index-headers.html | 0001636282-26-000075 |
| Document: 0001636282-26-000075-index.html | 0001636282-26-000075 |
| Document: 0001636282-26-000075.txt | 0001636282-26-000075 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access